首页> 外文期刊>Vaccine >Protective efficacy of a DNA vaccine construct encoding the VP2 gene of infectious bursal disease and a truncated HSP70 of Mycobacterium tuberculosis in chickens
【24h】

Protective efficacy of a DNA vaccine construct encoding the VP2 gene of infectious bursal disease and a truncated HSP70 of Mycobacterium tuberculosis in chickens

机译:编码传染性法氏囊病VP2基因和截短的结核分枝杆菌HSP70的DNA疫苗构建体对鸡的保护作用

获取原文
获取原文并翻译 | 示例
           

摘要

Infectious bursal disease (IBD) is an acute, infectious, immunosuppressive disease affecting young chicken worldwide. The etiological agent IBD virus (IBDV) is a double stranded RNA virus with outer capsid protein VP2 of IBDV is the major antigenic determinant capable of inducing neutralizing antibody. DNA vaccines encoding VP2 has been extensively studied achieving only partial protection. However, the efficacy of DNA vaccines against IBDV can be augmented by choosing a potential molecular adjuvant. The goal of the present study is to evaluate the immune response and protective efficacy of a DNA vaccine encoding the C-terminal domain of the heat shock protein 70 (cHSP70) of Mycobacterium tuberculosis gene genetically fused with the full length VP2 gene of IBDV (pCIVP2-cHSP70) in comparison to a 'DNA prime-protein boost' approach and a DNA vaccine encoding the VP2 gene (pCIVP2) alone. The results indicate that both pCIVP2-cHSP70 and 'DNA prime-protein boost' elicited humoral as well as cellular immune responses. Chickens in the pCIVP2-cHSP70 and 'DNA prime-protein boost' groups developed significantly higher levels of ELISA titer to IBDV antigen compared to the group immunized with pCIVP2 alone (p 0.01). However, significantly higher levels of lymphocyte proliferative response, IL-12 and IFN-gamma production were found in the pCIVP2-cHSP70 group compared to 'DNA prime-protein boost' group. Additionally, chickens immunized with pCIVP2-cHSP70 and 'DNA prime-protein boost' vaccines were completely protected against the vvIBDV whereas pCIVP2 DNA vaccine alone was able to protect only 70%. These findings suggest that the truncated C-terminal HSP70 mediated DNA vaccine genetically fused with the VP2 gene construct stimulated both humoral and cell mediated immune responses and conferred complete protection against IBDV. This novel strategy is perhaps a seminal concept in utilizing HSP70 as an adjuvant molecule to elicit an immune response against IBD affecting chickens. (C) 2015 Elsevier Ltd. All rights reserved.
机译:传染性法氏囊病(IBD)是一种急性,传染性,免疫抑制性疾病,影响全世界的雏鸡。病原体IBD病毒(IBDV)是一种双链RNA病毒,IBDV的外衣壳蛋白VP2是能够诱导中和抗体的主要抗原决定簇。已经广泛研究了编码VP2的DNA疫苗,仅实现部分保护。但是,可以通过选择潜在的分子佐剂来增强针对IBDV的DNA疫苗的功效。本研究的目的是评估编码结核分枝杆菌基因热休克蛋白70(cHSP70)C末端结构域与IBDV全长VP2基因(pCIVP2)基因融合的DNA疫苗的免疫应答和保护功效-cHSP70)与“ DNA原蛋白增强”方法和仅编码VP2基因(pCIVP2)的DNA疫苗相比。结果表明,pCIVP2-cHSP70和“ DNA初级蛋白增强”均引起体液和细胞免疫应答。与仅用pCIVP2免疫的组相比,在pCIVP2-cHSP70和“ DNA原蛋白加强”组中的鸡对IBDV抗原的ELISA效价水平显着提高(p <0.01)。然而,与“ DNA初级蛋白加强”组相比,pCIVP2-cHSP70组的淋巴细胞增殖反应,IL-12和IFN-γ产生水平明显更高。此外,用pCIVP2-cHSP70和'DNAprim-protein boost'疫苗免疫的鸡对vvIBDV完全受到保护,而仅pCIVP2 DNA疫苗仅能保护70%。这些发现表明,与VP2基因构建体遗传融合的截短的C末端HSP70介导的DNA疫苗刺激了体液和细胞介导的免疫反应,并赋予了针对IBDV的完全保护。这种新颖的策略可能是利用HSP70作为佐剂分子引发针对感染鸡的IBD的免疫应答的开创性概念。 (C)2015 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号